Altoida Announces Partnership with Click Therapeutics to Power Clinical Trials with Digital Cognitive Assessment
February 24, 2022 | Neelem Sheikh
At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
